These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32393286)

  • 41. CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma.
    Shen TX; Liu L; Li WH; Fu P; Xu K; Jiang YQ; Pan F; Guo Y; Zhang MC
    Cancer Imaging; 2019 Jun; 19(1):34. PubMed ID: 31174617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
    van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
    J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
    Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
    Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
    Li S; Zhao J; Wang Q
    J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
    Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
    Li J; Zhu L; Stebbing J; Peng L
    J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
    Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
    Niogret J; Coudert B; Boidot R
    J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
    [No Abstract]   [Full Text] [Related]  

  • 52. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
    Tamiya M; Kunimasa K; Nishino K; Matsumoto S; Kawachi H; Kuno K; Inoue T; Kuhara H; Imamura F; Goto K; Kumagai T
    Invest New Drugs; 2021 Feb; 39(1):232-236. PubMed ID: 32556898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next-generation sequencing assisted diagnosis of cervical metastasis in EGFR-mutated lung adenocarcinoma: A case report.
    Xu L; Li K; Chen X; Chen B; Li J; Wu L
    Thorac Cancer; 2021 Oct; 12(19):2622-2627. PubMed ID: 34505336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
    de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
    J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
    [No Abstract]   [Full Text] [Related]  

  • 57. Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.
    Liu Y; Wu Y; Wu F; Hu C
    Chemotherapy; 2022; 67(4):248-252. PubMed ID: 35764055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Miliary cerebral carcinomatosis secondary to EGFR mutation-positive lung adenocarcinoma].
    Dumoulin J; Rozensztajn N; Paradis M; Sellier J; Abel A; Giraud P; Labrune S; Chinet T
    Rev Mal Respir; 2016 Jan; 33(1):67-71. PubMed ID: 25794997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
    Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
    Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.